PCSK9 and diabetes mellitus: One Mendelian‐randomization study in ~113,000 subjects with average plasma LDL‐C of 3.36 mmol reported that LDL‐lowering variants in HMGCR, PCSK9, and LDLR were associated with a 10–13% rise in diabetes risk for every 0.26 mM decrease in plasma LDL‐C (Ference et al., 2016).